[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Adam Feuerstein ✡️ [@adamfeuerstein](/creator/twitter/adamfeuerstein) on x 119.4K followers Created: 2025-07-22 12:19:30 UTC Just in the past week, Takeda announced that two late-stage trials succeeded, and Alkermes disclosed its mid-stage study was positive, saying that its therapy helped patients reach normal levels of wakefulness. Along with Centessa Pharmaceuticals, the drugmakers are also testing orexin candidates in narcolepsy type X and idiopathic hypersomnia, other sleep conditions that the drugs have shown early potential to treat. In these three rare sleep disorders alone, analysts project a greater than $X billion market, with potential to grow even bigger as more patients seek diagnoses and treatment. XXXXX engagements  **Related Topics** [$alks](/topic/$alks) [Post Link](https://x.com/adamfeuerstein/status/1947632595648360598)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Adam Feuerstein ✡️ @adamfeuerstein on x 119.4K followers
Created: 2025-07-22 12:19:30 UTC
Just in the past week, Takeda announced that two late-stage trials succeeded, and Alkermes disclosed its mid-stage study was positive, saying that its therapy helped patients reach normal levels of wakefulness.
Along with Centessa Pharmaceuticals, the drugmakers are also testing orexin candidates in narcolepsy type X and idiopathic hypersomnia, other sleep conditions that the drugs have shown early potential to treat.
In these three rare sleep disorders alone, analysts project a greater than $X billion market, with potential to grow even bigger as more patients seek diagnoses and treatment.
XXXXX engagements
Related Topics $alks